$1.40
4.11% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US88338N1072
Symbol
TXMD
Sector
Industry

TherapeuticsMD, Inc. Stock price

$1.40
-0.13 8.34% 1M
-0.69 33.01% 6M
-0.85 37.78% YTD
-0.96 40.68% 1Y
-29.23 95.43% 3Y
-135.60 98.98% 5Y
-191.10 99.27% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.06 4.11%
ISIN
US88338N1072
Symbol
TXMD
Sector
Industry

Key metrics

Market capitalization $16.15m
Enterprise Value $18.50m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 11.56
P/S ratio (TTM) P/S ratio 10.09
P/B ratio (TTM) P/B ratio 0.60
Revenue (TTM) Revenue $1.60m
EBIT (operating result TTM) EBIT $-4.79m
Cash position $5.05m
EPS (TTM) EPS $-0.29
Short interest 0.35%
Show more

Is TherapeuticsMD, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

TherapeuticsMD, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast TherapeuticsMD, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast TherapeuticsMD, Inc.:

Hold
100%

Financial data from TherapeuticsMD, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.60 1.60
98% 98%
100%
- Direct Costs 1.05 1.05
94% 94%
66%
0.55 0.55
99% 99%
34%
- Selling and Administrative Expenses 4.30 4.30
101% 101%
269%
- Research and Development Expense - -
-
-
-3.75 -3.75
96% 96%
-234%
- Depreciation and Amortization 1.05 1.05
75% 75%
66%
EBIT (Operating Income) EBIT -4.79 -4.79
95% 95%
-299%
Net Profit -3.32 -3.32
62% 62%
-208%

In millions USD.

Don't miss a Thing! We will send you all news about TherapeuticsMD, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TherapeuticsMD, Inc. Stock News

Neutral
Business Wire
3 days ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) pe...
Neutral
Business Wire
3 months ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per b...

Company Profile

TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Head office United States
CEO Marlan Walker
Employees 1
Founded 1907
Website www.therapeuticsmd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today